Brief: Intra-Cellular Therapies Announces FDA Approval Of New Dosage Strengths For Caplyta For Specific Patient Populations

Intra-Cellular Therapies

25/04/2022 12:11

April 25 (Reuters) - Intra-Cellular Therapies Inc  ITCI.O :
    * INTRA-CELLULAR THERAPIES ANNOUNCES FDA APPROVAL OF NEW DOSAGE STRENGTHS
FOR
CAPLYTA® (LUMATEPERONE) FOR SPECIFIC PATIENT POPULATIONS
    * INTRA-CELLULAR THERAPIES INC - CAPLYTA'S NEW DOSAGE STRENGTHS ARE EXPECTED
TO BE
AVAILABLE IN PHARMACIES IN MID-2022

Source text for Eikon:  ID:nGNXbb6tG 
Further company coverage:  ITCI.O 

 ((Reuters.Briefs@thomsonreuters.com;))